Breaking News, Collaborations & Alliances

NorthStar Medical Radioisotopes Enter Strategic Supply Pact

NorthStar to provide Alpha-9 with its non-carrier added Actinium-225 (Ac-225) for use in development and clinical programs.

NorthStar Medical Radioisotopes, LLC, a company involved in the development, production and commercialization of radiopharmaceuticals, and Alpha-9 Oncology Inc., a clinical stage biotechnology company developing highly targeted radiopharmaceuticals to treat a range of cancers, entered into a long-term strategic supply agreement for NorthStar to provide Alpha-9 with its non-carrier added Actinium-225 (Ac-225) for use in its development and clinical programs.

“NorthStar, using its advanced electron accelerator technology, is on schedule to be one of the first commercial-scale producers of n.c.a. Ac-225,” said Frank Scholz, CEO of NorthStar Medical Radioisotopes. “The n.c.a. Ac-225 we produce is free of long-lived radioactive contaminants and byproducts associated with other production methods – contaminants that pose regulatory and waste management challenges for pharmaceutical companies, hospitals, and health systems.”

Scholz added: “NorthStar’s advanced technology and expertise in isotope production will accelerate Alpha-9’s ability to advance a number of innovative, specialized radiopharmaceuticals to benefit patients with solid tumors and a variety of blood cancers while minimizing unwanted off-target effects.”

David Hirsch, CEO of Alpha-9 Oncology said, “The Alpha-9 team is well positioned to progress multiple targets into the clinic. Robust supply of high-quality Ac-225 will help us advance a new generation of highly effective radiopharmaceuticals with improved tumor uptake and limited off-target exposure. We look forward to working with NorthStar and bringing our molecules to patients.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters